Supplementary Table 2.
VE and Noninferiority Assessment for the Risk of Different COVID-19 Criteria in Patients Who Received Ad.26.COV2.S, BNT162b2/mRNA-1273 Vaccines Versus Unvaccinated Control Subjects
| VE = 1-OR |
Symptomatic COVID-19 | Moderate/severe/critical COVID-19 | Severe/critical COVID-19 | |
|---|---|---|---|---|
| COVID-19 | ||||
| Ad.26.COV2.S | ||||
| Upper confidence limit | 0.64 | 0.68 | 0.7 | 0.72 |
| VE | 0.8 | 0.79 | 0.74 | 0.84 |
| LCL | 0.38 | 0.59 | 0.63 | 0.58 |
| BNT162b2 / mRNA-1273 | ||||
| Upper confidence limit | 0.73 | 0.78 | 0.8 | 0.82 |
| VE | 0.81 | 0.84 | 0.92 | 0.93 |
| LCL | 0.63 | 0.62 | 0.68 | 0.69 |
| 90% NIM | 0.567 | 0.558 | 0.612 | 0.621 |
| Conclude noninferiority LCL (Ad.26.COV2.S) <90% NIM |
No | Yes | Yes | No |
| 75% NIM | 0.4725 | 0.465 | 0.51 | 0.5175 |
| Conclude noninferiority LCL (Ad.26.COV2.S) <75% NIM |
No | Yes | Yes | Yes |
LCL, lower confidence limit; NIM, noninferiority margin; VE, vaccine efficacy.